ENTRY       D01161                      Drug
NAME        Fulvestrant (JAN/USP/INN);
            Faslodex (TN)
PRODUCT     FASLODEX (AstraZeneca Pharmaceuticals LP)
            FULVESTRANT (Actavis Pharma)
            FULVESTRANT (Fresenius Kabi USA)
  GENERIC   FULVESTRANT (Accord Healthcare)
            FULVESTRANT (Alembic Pharmaceuticals)
            FULVESTRANT (Amneal Pharmaceuticals LLC)
            FULVESTRANT (Athenex Pharmaceutical Division)
            FULVESTRANT (BluePoint Laboratories)
            FULVESTRANT (BluePoint Laboratories)
            FULVESTRANT (Chia Tai Tianqing Pharmaceutical Group)
            FULVESTRANT (Dr.Reddy's Laboratories)
            FULVESTRANT (Eugia US LLC)
            FULVESTRANT (GLENMARK PHARMACEUTICALS)
            FULVESTRANT (Hikma Pharmaceuticals USA)
            FULVESTRANT (Meitheal Pharmaceuticals)
            FULVESTRANT (NorthStar Rx LLC)
            FULVESTRANT (Northstar Rx)
            FULVESTRANT (Sandoz)
            FULVESTRANT (Sandoz)
            FULVESTRANT (Sandoz)
            FULVESTRANT (Xiromed)
            FULVESTRANT (Zydus Lifesciences Limited)
            FULVESTRANT (Zydus Pharmaceuticals USA)
FORMULA     C32H47F5O3S
EXACT_MASS  606.3166
MOL_WEIGHT  606.7708
CLASS       Antineoplastic
             DG01585  Estrogen receptor antagonist
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 4291
            ATC code: L02BA03
            Product: D01161<JP/US>
EFFICACY    Antineoplastic, Estrogen receptor agonist/antagonist
  DISEASE   Breast cancer, postmenopausal (HR positive) [DS:H00031]
            Breast cancer, postmenopausal (HR positive, HER2 negative) [DS:H00031]
TARGET      NR3A (ESR) [HSA:2099 2100] [KO:K08550 K08551]
  PATHWAY   hsa04915(2099+2100)  Estrogen signaling pathway
            hsa05200(2099+2100)  Pathways in cancer
            hsa05224(2099+2100)  Breast cancer
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
STR_MAP     map07043  Antineoplastics - hormones
            map07226  Progesterone, androgen and estrogen receptor agonists/antagonists
OTHER_MAP   map01522  Endocrine resistance
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L02 ENDOCRINE THERAPY
               L02B HORMONE ANTAGONISTS AND RELATED AGENTS
                L02BA Anti-estrogens
                 L02BA03 Fulvestrant
                  D01161  Fulvestrant (JAN/USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Antiestrogens/Modifiers
               Fulvestrant
                D01161  Fulvestrant (JAN/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D01161  Fulvestrant (JAN/USP/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01585  Estrogen receptor antagonist
               D01161  Fulvestrant
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D01161  Fulvestrant
            Drug classes [BR:br08332]
             Antineoplastic
              DG01585  Estrogen receptor antagonist
               D01161  Fulvestrant
            Target-based classification of drugs [BR:br08310]
             Nuclear receptors
              Estrogen like receptors
               Estrogen receptor
                NR3A (ESR)
                 D01161  Fulvestrant (JAN/USP/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D01161
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D01161
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D01161
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D01161
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D01161
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D01161
DBLINKS     CAS: 129453-61-8
            PubChem: 7848224
            ChEBI: 31638
            PDB-CCD: FVS
            LigandBox: D01161
            NIKKAJI: J401.163E
ATOM        41
            1   C8x C     7.4203  -16.5528
            2   C8y C     7.4203  -17.9330
            3   C8x C     8.6185  -18.6231
            4   C8x C     8.6185  -15.8628
            5   C8y C     9.8096  -16.5528
            6   C8y C     9.8037  -17.9330
            7   C1x C    10.9960  -18.6281
            8   C1y C    12.1942  -17.9432
            9   C1y C    11.0077  -15.8679
            10  C1y C    12.1942  -16.5658
            11  C1x C    12.2169  -13.8129
            12  C1x C    11.0191  -14.4913
            13  C1z C    13.4035  -14.5109
            14  C1y C    13.3866  -15.8831
            15  C1x C    15.7638  -15.9121
            16  C1x C    15.7803  -14.5396
            17  C1y C    14.6003  -13.8392
            18  O1a O    14.7331  -12.4541
            19  O1a O     6.2253  -18.6237
            20  C1b C    13.3801  -18.6301
            21  C1b C    14.5721  -17.9469
            22  C1b C    15.7641  -18.6370
            23  C1b C    16.9561  -17.9539
            24  C1b C    18.1480  -18.6440
            25  C1b C    19.3400  -17.9609
            26  C1b C    20.5319  -18.6510
            27  C1b C    21.7239  -17.9678
            28  C1b C    22.9159  -18.6579
            29  S4a S    24.1078  -17.9748
            30  C1b C    25.2998  -18.6649
            31  C1b C    26.4917  -17.9819
            32  C1b C    27.6837  -18.6720
            33  C1d C    28.8756  -17.9887
            34  O3c O    24.1108  -16.5946
            35  X   F    29.9914  -17.2156
            36  X   F    27.8928  -17.0058
            37  C1a C    13.3941  -13.1303
            38  C1d C    29.8649  -18.9778
            39  X   F    30.8541  -19.9671
            40  X   F    31.0764  -18.2784
            41  X   F    28.6534  -19.6773
BOND        44
            1     4   1 1
            2     2  19 1
            3     1   2 2
            4     8  20 1 #Down
            5     9  10 1
            6    20  21 1
            7    10  14 1
            8    21  22 1
            9    13  11 1
            10   22  23 1
            11   11  12 1
            12   23  24 1
            13   12   9 1
            14   24  25 1
            15    2   3 1
            16   25  26 1
            17    3   6 2
            18   26  27 1
            19    5   6 1
            20   27  28 1
            21    6   7 1
            22   28  29 1
            23    7   8 1
            24   29  30 1
            25   13  14 1
            26   30  31 1
            27   15  16 1
            28   31  32 1
            29   16  17 1
            30   32  33 1
            31   17  13 1
            32   29  34 2
            33   14  15 1
            34    8  10 1
            35   17  18 1 #Up
            36    9   5 1
            37   33  35 1
            38    5   4 2
            39   33  36 1
            40   13  37 1 #Up
            41   33  38 1
            42   38  39 1
            43   38  40 1
            44   38  41 1
///
